A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
Latest Information Update: 12 Feb 2024
At a glance
- Drugs AZD 7648 (Primary) ; Doxorubicin liposomal; Olaparib
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; First in man; Proof of concept
- Sponsors AstraZeneca
Most Recent Events
- 17 Jan 2023 Status changed from active, no longer recruiting to completed.
- 10 Aug 2022 Planned End Date changed from 26 Feb 2024 to 26 Dec 2022.
- 10 Aug 2022 Planned primary completion date changed from 26 Feb 2024 to 26 Dec 2022.